These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16880168)

  • 21. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy.
    Huang W; De Gruttola V; Fischl M; Hammer S; Richman D; Havlir D; Gulick R; Squires K; Mellors J
    J Infect Dis; 2001 May; 183(10):1455-65. PubMed ID: 11319681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
    PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
    Kim S; Hughes MD; Hammer SM; Jackson JB; DeGruttola V; Katzenstein DA
    AIDS Res Hum Retroviruses; 2000 May; 16(7):645-53. PubMed ID: 10791875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.
    Laurent C; Kouanfack C; Laborde-Balen G; Aghokeng AF; Mbougua JB; Boyer S; Carrieri MP; Mben JM; Dontsop M; Kazé S; Molinari N; Bourgeois A; Mpoudi-Ngolé E; Spire B; Koulla-Shiro S; Delaporte E;
    Lancet Infect Dis; 2011 Nov; 11(11):825-33. PubMed ID: 21831714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing resistance costs of antiretroviral therapies via measures of future drug options.
    Jiang H; Deeks SG; Kuritzkes DR; Lallemant M; Katzenstein D; Albrecht M; DeGruttola V
    J Infect Dis; 2003 Oct; 188(7):1001-8. PubMed ID: 14513420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs.
    Murray JS; Elashoff MR; Iacono-Connors LC; Cvetkovich TA; Struble KA
    AIDS; 1999 May; 13(7):797-804. PubMed ID: 10357378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial.
    Gilbert PB; Ribaudo HJ; Greenberg L; Yu G; Bosch RJ; Tierney C; Kuritzkes DR
    AIDS; 2000 Sep; 14(13):1961-72. PubMed ID: 10997401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.
    Greub G; Cozzi-Lepri A; Ledergerber B; Staszewski S; Perrin L; Miller V; Francioli P; Furrer H; Battegay M; Vernazza P; Bernasconi E; Günthard HF; Hirschel B; Phillips AN; Telenti A;
    AIDS; 2002 Sep; 16(14):1967-9. PubMed ID: 12351960
    [No Abstract]   [Full Text] [Related]  

  • 35. The cytology of HIV-induced immunosuppression. Changing pattern of disease in the era of highly active antiretroviral therapy.
    Kocjan G; Miller R
    Cytopathology; 2001 Oct; 12(5):281-96. PubMed ID: 11722508
    [No Abstract]   [Full Text] [Related]  

  • 36. Mixture models for quantitative HIV RNA data.
    Moulton LH; Curriero FC; Barroso PF
    Stat Methods Med Res; 2002 Aug; 11(4):317-25. PubMed ID: 12197299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases.
    Flandre P; Durier C; Descamps D; Launay O; Joly V
    J Acquir Immune Defic Syndr; 2002 May; 30(1):59-64. PubMed ID: 12048363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases.
    Marschner IC; Betensky RA; DeGruttola V; Hammer SM; Kuritzkes DR
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):220-7. PubMed ID: 10077169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping.
    Zackin R; Marschner I; Andersen J; Cowles MK; De Gruttola V; Hammer S; Fischl M; Cotton D
    J Infect Dis; 1998 Mar; 177(3):761-5. PubMed ID: 9498459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral suppression in HIV studies: combining times to suppression and rebound.
    Gouskova NA; Cole SR; Eron JJ; Fine JP
    Biometrics; 2014 Jun; 70(2):441-8. PubMed ID: 24446693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.